Biotechnology company Avidity Biosciences, Inc. (RNA) surged 6.7% in early trading after announcing the completion of pricing for a $600 million equity offering aimed at advancing its clinical programs and expanding commercial infrastructure. The proceeds will be utilized to support the development of its AOC platform and potential product commercialization, establishing a foundation for the company's future growth.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.